Log in to save to my catalogue

AB0416 SUBCUTANEUS VS INTRAVENOUS ABATACEPT IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIO...

AB0416 SUBCUTANEUS VS INTRAVENOUS ABATACEPT IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIO...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2853221621

AB0416 SUBCUTANEUS VS INTRAVENOUS ABATACEPT IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 392 PATIENTS

Publication information

Publisher

Kidlington: Elsevier B.V

More information

Scope and Contents

Contents

Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in RA-ILD [1-2]. Clinical trials have shown equivalence in subcutaneous (SC) and intravenous (IV) administration of ABA for articular manifestations [3]. However, it has not been studied in RA-ILD.
to...

Alternative Titles

Full title

AB0416 SUBCUTANEUS VS INTRAVENOUS ABATACEPT IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 392 PATIENTS

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2853221621

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2853221621

Other Identifiers

ISSN

0003-4967

E-ISSN

1468-2060

DOI

10.1136/annrheumdis-2023-eular.5219

How to access this item